New hope for kids with kidney disease: experimental drug aims to cut protein leak

NCT ID NCT06994845

Recruiting now Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called iptacopan in 31 children aged 2 to under 18 with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug reduces protein in the urine, a sign of kidney damage, and to check its safety and how the body processes it. Participants will take the drug and be monitored for about 6 months. This is not a cure, but aims to control the disease and prevent worsening.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

IgA glomerulonephritis proteinuria

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN)

Contacts and locations

Locations

Childrens Hospital Colorado
RECRUITING

Aurora, Colorado, 80045, United States
Childrens Hospital of Philadelphia
RECRUITING

Philadelphia, Pennsylvania, 19104-4399, United States
Novartis Investigative Site
RECRUITING

Brisbane, Queensland, 4101, Australia
Novartis Investigative Site
RECRUITING

Nedlands, Western Australia, 6009, Australia
Novartis Investigative Site
RECRUITING

Hangzhou, Zhejiang, 310052, China
Novartis Investigative Site
RECRUITING

Beijing, 100034, China
Novartis Investigative Site
RECRUITING

Hong Kong, 999077, Hong Kong
Novartis Investigative Site
RECRUITING

Beersheba, 8457108, Israel
Novartis Investigative Site
RECRUITING

Haifa, 3109601, Israel
Novartis Investigative Site
RECRUITING

Jerusalem, 9103102, Israel
Novartis Investigative Site
RECRUITING

Petah Tikva, 4920235, Israel
Novartis Investigative Site
RECRUITING

Toyoake, Aichi-ken, 4701192, Japan
Novartis Investigative Site
RECRUITING

Kurume, Fukuoka, 830-0011, Japan
Novartis Investigative Site
RECRUITING

Ohtsu, Shiga, 5202192, Japan
Novartis Investigative Site
RECRUITING

Fuchū, Tokyo, 1838561, Japan
Novartis Investigative Site
RECRUITING

Riyadh, 11211, Saudi Arabia
Prim Childrens Hosp Inv Pharm
RECRUITING

Salt Lake City, Utah, 84113, United States